A
Alison Stopeck
Researcher at Stony Brook University
Publications - 175
Citations - 12750
Alison Stopeck is an academic researcher from Stony Brook University. The author has contributed to research in topics: Breast cancer & Denosumab. The author has an hindex of 40, co-authored 159 publications receiving 11476 citations. Previous affiliations of Alison Stopeck include University of Arizona.
Papers
More filters
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison Stopeck,Allan Lipton,Jean-Jacques Body,Guenther G. Steger,Katia Tonkin,Richard De Boer,Mikhail Lichinitser,Yasuhiro Fujiwara,Denise A. Yardley,María Viniegra,Michelle Fan,Qi Jiang,Roger Dansey,Susie Jun,Ada Braun +14 more
TL;DR: With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
Journal ArticleDOI
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
Fred Saad,Janet E. Brown,C. Van Poznak,Toni Ibrahim,Salomon M. Stemmer,Alison Stopeck,Ingo Diel,Shunji Takahashi,Neal D. Shore,David H. Henry,Carlos H. Barrios,T. Facon,Francis M. Senecal,Karim Fizazi,Lei Zhou,Alan H. Daniels,P. Carriere,Roger Dansey +17 more
TL;DR: In this combined analysis of three prospective trials, Osteonecrosis of the jaw was infrequent, management was mostly conservative, and healing occurred in over one-third of the patients.
Journal ArticleDOI
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton,Karim Fizazi,Alison Stopeck,David H. Henry,Janet E. Brown,Denise A. Yardley,Gary Richardson,Salvatore Siena,Pablo Maroto,Michael Clemens,Boris Bilynskyy,Veena Charu,Philippe Beuzeboc,Michael Rader,María Viniegra,Fred Saad,Chunlei Ke,Ada Braun,Susie Jun +18 more
TL;DR: Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer.
Journal ArticleDOI
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years
Paul E. Goss,James N. Ingle,Kathleen I. Pritchard,Nicholas J. Robert,Hyman B. Muss,Julie R. Gralow,Karen A. Gelmon,Timothy J. Whelan,Kathrin Strasser-Weippl,Sheldon Rubin,Keren Sturtz,Antonio C. Wolff,Eric P. Winer,Clifford A. Hudis,Alison Stopeck,J. Thaddeus Beck,Judith S. Kaur,Kate Whelan,Dongsheng Tu,Wendy R. Parulekar +19 more
TL;DR: The extension of treatment with an adjuvant aromatase inhibitor to 10 years resulted in significantly higher rates of disease-free survival and a lower incidence of contralateral breast cancer than those with placebo, but the rate of overall survival was not higher with the aromat enzyme inhibitor than with placebo.